A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia
布鲁顿酪氨酸激酶抑制剂Zanubrutinib (BGB-3111)治疗复发/难治性华氏巨球蛋白血症患者的II期临床试验
期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-21-0539
An, Gang; Zhou, Daobin; Cheng, Shu; Zhou, Keshu; Li, Jianyong; Zhou, Jianfeng; Xie, Liping; Jin, Jie; Zhong, Liye; Yan, Lingzhi; Guo, Haiyi; Du, Chenmu; Zhong, Jinhua; Yu, Yiling; Wu, Binghao; Qiu, Lugui
